Study to Identify and Validate Biomarkers Linked to Severity in Adults Hospitalized With Respiratory Syncytial Virus Infection

What this Trial Is About

Respiratory Syncytial Virus RSV is a common cause of respiratory infections and is a leading viral cause of lower respiratory tract infection in infants. It also causes significant illness and death in adults, especially older adults, people with heart or lung diseases, and those with weakened immune systems. Researchers are studying how different RSV viral factors and genetic variations affect the severity of infection in hospitalized adults to help guide future treatment decisions. This observational study aims to identify and confirm biomarkers linked to severe RSV infection and to understand the viruss genetic diversity during illness. The study follows adults hospitalized with RSV infection for up to 28 days. Participants will have nasopharyngeal swabs collected at several times on the day of inclusion, days 3-4, days 5-7, and day 14. Blood samples will also be taken at the start for detailed immune and genetic testing. The first 100 patients will form a development group and the last 100 patients a validation group. A control group of patients admitted with acute respiratory symptoms but without RSV infection will also be included. During the study, researchers will analyze immune and inflammatory responses within the first 72 hours of hospital admission and throughout the stay up to 28 days. They will also study RSV genetic changes during hospitalization. Patients will be monitored closely through sample collections and clinical assessments. The main goal is to better understand how RSV infection progresses in adults and identify signs that predict severity, helping to improve future care and treatments.

Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV